Illumina Introduces TruSeq® Amplicon - Cancer Panel for MiSeq® System
March 07 2012 - 6:30AM
Business Wire
Illumina (NASDAQ:ILMN) today introduced the TruSeq Amplicon -
Cancer Panel, a highly multiplexed panel that will allow
researchers to accurately sequence hundreds of the most relevant
cancer loci, even in difficult samples such as formalin-fixed,
paraffin embedded (FFPE) tumor samples. With the ability to detect
mutations below 5% frequency, the TruSeq Amplicon assay provides
the highest quality data across many samples, all in one
experiment.
“The TruSeq Amplicon - Cancer Panel is an important advancement
for clinical researchers, enabling them to conduct in a matter of
days cancer studies that were previously impractical,” said
Christian Henry, Senior Vice President and General Manager of
Illumina’s Genomics Solutions Business. “Combined with the
accuracy, speed, and ease of use of the MiSeq personal sequencer,
this powerful new solution will help unlock millions of FFPE
samples as our customers seek to elucidate the biological
complexity of cancer.”
In a single experiment, researchers can access the most content
on any commercially available amplicon cancer panel, including key
genes that are associated with drug response and sensitivity.
Mutations in such genes are linked to many cancers, including
melanoma, lung cancer, ovarian cancer, and colorectal cancer. The
TruSeq Amplicon - Cancer Panel also delivers confidence and
simplicity with up front FFPE sample quality control, built-in
assay controls, and on-instrument automated analysis for variant
calling.
“In tests on real tumor samples, we confirmed all previously
detected mutations,” said Dr. Andrew Fellowes, of the Department of
Pathology at the Peter MacCallum Cancer Centre in Melbourne,
Australia. “This targeted panel on the MiSeq system will enable us
to profile tumor samples for a wider range of mutations and with
greater speed and sensitivity than is possible with our current
technology.”
The MiSeq system utilizes TruSeq, the industry’s most trusted
and accurate sequencing chemistry, powering over 2,300 scientific
publications. TruSeq targeted resequencing products offer complete,
end-to-end, cost effective solutions for any study design, with
pre-kitted reagents, simple workflows and validated multliplexed
sample processing.
Intended for research use only, the TruSeq Amplicon - Cancer
Panel is complementary to the strategy of Illumina's recently
created Translational and Consumer Genomics (TCG) business, which
is focused on delivering genomic solutions to CLIA labs. The TCG
has begun to partner with clinical thought leaders to develop
targeted resequencing panels for both MiSeq and HiSeq® systems,
building on the current TruSeq Amplicon and TruSeq Enrichment
assays, including extensions of the content that comprises the
TruSeq Amplicon - Cancer Panel.
The TruSeq Amplicon - Cancer Panel is now available for order
and will begin shipping in April 2012.
For more information, please visit
www.illumina.com/truseq_cancer_panel.
About Illumina
Illumina (www.illumina.com) is a leading developer,
manufacturer, and marketer of life science tools and integrated
systems for the analysis of genetic variation and function. We
provide innovative sequencing and array-based solutions for
genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA,
and protein. We also provide tools and services that are fueling
advances in consumer genomics and diagnostics. Our technology and
products accelerate genetic analysis research and its application,
paving the way for molecular medicine and ultimately transforming
healthcare.
Forward-Looking Statements
This release contains forward looking statements that involve
risks and uncertainties. Important factors that could cause actual
results to differ materially from those in any forward-looking
statements are detailed in our filings with the Securities and
Exchange Commission, including our most recent filings on Forms
10-K and 10-Q, or in information disclosed in public conference
calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date
of this release.
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From May 2024 to Jun 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Jun 2023 to Jun 2024